NASDAQ : LBRX
LB Pharmaceuticals Inc — Key statistics
Healthcare · Biotechnology · United States
Last price 39.7 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.28B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.28B |
| Enterprise Value | 958.12M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 32.26M |
| Shares Outstanding | 32.26M |
| Shares Change (YoY) | +8,821.45% |
| Shares Change (QoQ) | +6.71% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 83.59% |
| Float | 26.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 15.08 |
| Quick Ratio | 13.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -50.00% |
| Return on Assets (ROA) | -29.98% |
| Return on Invested Capital (ROIC) | -32.48% |
| Return on Capital Employed (ROCE) | -27.02% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | +153.67% |
| 50-Day Moving Average | 41.38 |
| 200-Day Moving Average | 32.58 |
| Relative Strength Index (RSI) | 52.93 |
| Average Volume (20 Days) | 421,790 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.56M |
| Short Previous Month | 6.01M |
| Short % of Shares Out | 17.25% |
| Short % of Float | 21.03% |
| Short Ratio (days to cover) | 12.64 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -91.38M |
| Pretax Income | -85.68M |
| Net Income | -85.69M |
| EBITDA | -91.03M |
| EBIT | -91.38M |
| Earnings Per Share (EPS) | -$3.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 327.79M |
| Total Debt | 5.22M |
| Net Cash | 322.57M |
| Net Cash Per Share | $10.00 |
| Equity (Book Value) | 332.35M |
| Book Value Per Share | 11.59 |
| Working Capital | 331.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -82.40M |
| Capital Expenditures | -435,000 |
| Depreciation & Amortization | 345,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -82.83M |
| FCF Per Share | -$2.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8,821.45% |
| Shareholder Yield | -8,821.45% |
| Earnings Yield | -9.61% |
| FCF Yield | -6.47% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $58.00 |
| Price Target Difference | 46.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |